Advertisement

Investigational New Drugs

, Volume 34, Issue 5, pp 650–653 | Cite as

Intravitreal vascular endothelial growth factor (VEGF) inhibitor injection in unrecognised early pregnancy

  • Farzan Kianersi
  • Heshmatollah Ghanbari
  • Zahra Naderi Beni
  • Afsaneh Naderi BeniEmail author
SHORT REPORT

Summary

The use of intravitreal vascular endothelial growth factor (VEGF) inhibitor medications has widened considerably to include indications affecting females of reproductive age. Our patient was inadvertently exposed to bevacizumab within the first trimester when placental growth and fetal organogenesis take place and patient suffered pregnancy loss. There is insufficient information to suggest that such use is safe, nor is there definitive evidence to suggest that it causes harm. We advise that ophthalmologists discuss pregnancy with women of childbearing age undergoing intraocular anti-VEGF injections and in pregnant woman counselling is needed to explain the potential risks and benefits.

Keywords

Intravitreal vascular endothelial growth factor Pregnancy Complication 

Notes

Compliance with ethical standards

Conflict of interest

Authors do not have any financial interest in the subject matter of this article.

References

  1. 1.
    Falavarjani KG, Nguyen QD (2013) Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond) 27(7):787–794CrossRefGoogle Scholar
  2. 2.
    Sawada O, Kawamura H, Kakinoki M, Ohji M (2008) Vascular endothelial growth factor in fellow eyes of eyes injected with intravitreal bevacizumab. Graefes Arch Clin Exp Ophthalmol 246:1379–1381CrossRefPubMedGoogle Scholar
  3. 3.
    Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ (2007) Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 114:855–859CrossRefPubMedGoogle Scholar
  4. 4.
    Wang D (2014) Kyung Seek Choi, and Sung Jin Lee. Serum Concentration of Vascular Endothelial Growth Factor after Bilateral Intravitreal Injection of Bevacizumab -Korean J Ophthalmol. 28(1):32–38PubMedGoogle Scholar
  5. 5.
    E Rosen, A Rubowitz and J R Ferencz..Exposure to verteporfin and bevacizumab therapy for choroidal neovascularization secondary to punctate inner choroidopathy during pregnancy. Eye (2009) 23, 1479; doi: 10.1038/eye.2008.218
  6. 6.
    Tarantola RM, Folk JC, Boldt HC, Mahajan VB (2010) Intravitreal bevacizumab during pregnancy. Retina 30(9):1405–1411CrossRefPubMedGoogle Scholar
  7. 7.
    Wu Z, Huang J, Sadda S (2010) Inadvertent use of bevacizumab to treat choroidal neovascularisation during pregnancy: a case report. Ann Acad Med Singap 39(2):143–145PubMedGoogle Scholar
  8. 8.
    Introini U, Casalino G, Cardani A, Scotti F, Finardi A, Candiani M, Bandello F (2012) Intravitreal bevacizumab for a subfoveal myopic choroidal neovascularization in the first trimester of pregnancy. J Ocul Pharmacol Ther 28(5):553–555CrossRefPubMedGoogle Scholar
  9. 9.
    Sarhianaki A, Katsimpris A, Petropoulos IK, Livieratou A, Theoulakis PE, Katsimpris JM (2012) Intravitreal administration of ranibizumab for idiopathic choroidal neovascularization in a pregnant woman. Klin Monatsbl Augenheilkd 229(4):451–453CrossRefPubMedGoogle Scholar
  10. 10.
    Petrou P, Georgalas I, Giavaras G, Anastasiou E, Ntana Z, Petrou C (2010) Early loss of pregnancy after intravitreal bevacizumab injection. Acta Ophthalmol 88(4):e136CrossRefPubMedGoogle Scholar
  11. 11.
    Sullivan L, Kelly SP, Glenn A, Williams CP, McKibbin M1.Intravitreal bevacizumab injection in unrecognised early pregnancy. Eye (Lond). 2014 ;28(4):492–4Google Scholar
  12. 12.
    Csaky K, Do DV (2009) Safety implications of vascular endothelial growth factor blockade for subjects receiving intravitreal anti-vascular endothelial growth factor therapies. Am J Ophthalmol 148:647–656CrossRefPubMedGoogle Scholar
  13. 13.
    Fung AE, Rosenfeld PJ & Reichel E (2006): The international bevacizumab safety survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 90: 1344–1349.Google Scholar
  14. 14.
    Wu L, Martinez-Castellanos MA, Quiroz- Mercado H et al. (2007): Twelve-month safety of intravitreal injections of bevacizumab (Avastin_): results of the pan- American collaborative retina study group (PACORES). Graefes Arch Clin Exp Ophthalmol (in press).Google Scholar
  15. 15.
    Thorn M, Piche-Nicholas N, Stedman D, Davenport SW, Zhang N, Collinge M (2012) Bowman CJEmbryo-fetal transfer of bevacizumab (Avastin) in the rat over the course of gestation and the impact of neonatal fc receptor (FcRn) binding. Birth Defects Res B Dev Reprod Toxicol 95(5):363–375CrossRefPubMedGoogle Scholar
  16. 16.
    Briggs GG, Freeman RK, Yaffe SJ (2011) Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. 9th ed. Wolters Kluwer/Lippincott Williams & Wilkins, PhiladelphiaGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Farzan Kianersi
    • 1
  • Heshmatollah Ghanbari
    • 1
  • Zahra Naderi Beni
    • 2
  • Afsaneh Naderi Beni
    • 3
    Email author
  1. 1.Department of OphthalmologyIsfahan University of Medical SciencesIsfahanIran
  2. 2.Department of Oncology and RadiotherapyIsfahan University of Medical SciencesIsfahanIran
  3. 3.Department of OphthalmologyShahrekord University of Medical SciencesShahrekordIran

Personalised recommendations